Use the hyperlinks, where available to access additional clinical trial information.
A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma
This is a modular dose confirmation and expansion study. Module 1 of this study will evaluate how safe, tolerable and effective AZD4573 is as monotherapy. Eligible participants will be split into three cohorts depending on their diagnosis, and all participants will receive AZD4573 as monotherapy via intravenous infusion. If AZD4573 monotherapy is found to have promising anti-cancer effectiveness in Module 1, an AZD4573 monotherapy Phase II expansion may be added.